[CH3:1][N:2]1[C:7](=[O:8])[C:6]2[C:9]([C:12]([O:14][CH2:15][CH3:16])=[O:13])=[CH:10][S:11][C:5]=2[N:4]([CH2:17][CH:18]([CH3:20])[CH3:19])[C:3]1=[O:21].[Cl:22][C:23]1[S:24][C:25]([CH:29]=[O:30])=[C:26]([Cl:28])[N:27]=1.CN1C(=O)N(C)CCC1.[Li+].CC([N-]C(C)C)C>C1COCC1.C(O)(=O)C>[Cl:22][C:23]1[S:24][C:25]([CH:29]([OH:30])[C:10]2[S:11][C:5]3[N:4]([CH2:17][CH:18]([CH3:20])[CH3:19])[C:3](=[O:21])[N:2]([CH3:1])[C:7](=[O:8])[C:6]=3[C:9]=2[C:12]([O:14][CH2:15][CH3:16])=[O:13])=[C:26]([Cl:28])[N:27]=1To a solution of ethyl 3-methyl-1-(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-5-carboxylate (1.5 g), 2,4-dichlorothiazole-5-carboxaldehyde (1.75 g) and DMPU (1.2 ml) in THF (25 ml) at −78° C., was added LDA (10 mmol). Acetic acid (3 ml) was added and the mixture allowed to warm to ambient temperature. The mixture was then partitioned between ethyl acetate and water, the organics were collected, dried over magnesium sulphate and concentrated to dryness. The residue was purified by normal phase chromatography (3:1 i-hexane:ethyl acetate) to give the sub-title compound as a yellow foam (0.45 g).